Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA fragmentation factor subunit beta (DFFB)
- Target
- DFFB
- Molecular classification
- Enzyme, Endonuclease, Caspase-activated nuclease
01
Overview
DNA fragmentation factor subunit beta (DFFB) is an essential enzyme in the apoptosis pathway, functioning as the active nuclease responsible for fragmenting chromosomal DNA during programmed cell death. It forms a heterodimer with DFFA (its inhibitor), with activation occurring via caspase-3-mediated cleavage of the inhibitory partner, freeing DFFB to execute DNA cleavage and enable chromatin condensation. DFFB is highly conserved and broadly expressed, and its dysfunction is associated with cancer, neurodegeneration, and autoimmune disease. Therapeutic interest centers on its role in apoptosis, genomic stability, and cellular response to DNA-damaging agents
- Other names
- DFFBDFF40DFF-40CADCaspase-activated DNaseCaspase-activated deoxyribonucleaseCaspase-activated nucleaseCPANDFF2DNA fragmentation factor 40 kDa subunitDNA fragmentation factor, 40kDa, beta polypeptide (caspase-activated DNase)
02
Mechanism of action
Drugs or molecules modulating DFFB might block or induce apoptosis via inhibition or activation of DNA fragmentation
03
Biological functions
Apoptosis (programmed cell death)DNA fragmentationChromatin condensationCell differentiationNuclear remodeling
04
Disease associations
CancerNeurodegenerative diseaseAutoimmune diseaseChemotherapy resistance
05
Safety considerations
Targeting DFFB or manipulating apoptotic DNA fragmentation could risk off-target cell death, tissue damage, or genomic instability
06
Biomarkers
DFFB expression level (potential in chemotherapy resistance, particularly cisplatin resistance)
Beyond the preview
Go deeper on DNA fragmentation factor subunit beta (DFFB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA fragmentation factor subunit beta (DFFB).